The Atlantic

The Strongest Evidence Yet That America Is Botching Coronavirus Testing

“I don’t know what went wrong,” a former CDC chief told The Atlantic.

It’s one of the most urgent questions in the United States right now: How many people have actually been tested for the coronavirus?

This number would give a sense of how widespread the disease is, and how forceful a response to it the United States is mustering. But for days, the Centers for Disease Control and Prevention has refused to publish such a count, despite public anxiety and criticism from Congress. On Monday, Stephen Hahn, the commissioner of the Food and Drug Administration, estimated that “by the end of this week, close to a million tests will be able to be performed” in the United States. On Wednesday, Vice President Mike Pence promised that “roughly 1.5 million tests” would be available this week.

But the number of tests performed across the country has fallen far short of those projections, despite extraordinarily high demand, The Atlantic has found.

“The CDC got this right with H1N1 and Zika, and produced huge quantities of test kits that went around the country,” Thomas Frieden, the director of the CDC from 2009 to 2017, told us. “I don’t know what went wrong this time.”

Related: The Official Numbers on the Coronavirus Are Wrong, and Everyone Knows It

Related: We Can Still Avoid the Worst-Case Coronavirus Scenario

Related: Epidemics Reveal the Truth of the Societies They Hit

Through interviews with dozens of public-health officials and a survey of local data from across the country, The Atlantic could only verify that 1,895 people have been tested for the coronavirus in the United States, about 10 percent of whom have tested positive. And while the American capacity to test for the coronavirus has ramped up significantly over the past few days, local officials can still test only several thousand people a day, not the tens or hundreds of thousands indicated by the White House’s promises.

To arrive at our estimate, we contacted the public-health departments of all 50 states and the District of Columbia. We gathered data on websites, and we corresponded with dozens of state officials. All 50 states and D.C. have made some information available, though the quality and timeliness of the data varied widely. Some states have only committed to releasing their numbers once or three times a week. Most are focused on the number of confirmed cases; only a few have publicized the number of people they are capable of testing.

The Atlantic’s numbers reflect the best available portrait of the country’s testing capacity as of early this morning. These numbers provide an accurate baseline, but they are incomplete. Scattered on state websites, the data available are not useful to citizens or political leaders. State-based tallies lack the reliability of the CDC’s traditional—but now abandoned—method of reporting. Several states—including New Jersey, Texas, and Louisiana—have not shared the number of coronavirus tests they have conducted overall, meaning their number of positive results lacks crucial context.

The net effect of these choices is that the country’s true capacity for testing has not been made clear to its residents. This level of obfuscation is unexpected in the United States, which has long been a global leader in public-health transparency.

The figures we gathered suggest that the American response to the coronavirus and the disease it causes, COVID-19, has been shockingly sluggish, especially compared with that of other developed countries. The CDC confirmed eight days ago that the virus was in community transmission in the United States—that it was infecting Americans who had neither traveled abroad nor were in contact with others who had. In South Korea, more than 66,650 people were tested within a week of its first case of community transmission, and it quickly became able to test 10,000 people a day. The United Kingdom, which has only 115 positive cases, has so far tested 18,083 people for the virus.

Normally, the job of gathering these types of data in the U.S. would be left to epidemiologists at the CDC. The agency regularly collects and publishes positive and negative test results for several pathogens, including multiple types of the seasonal flu. But earlier this week, the agency announced that it would stop publishing negative results for the coronavirus, an extraordinary step that essentially keeps Americans from knowing how many people have been tested overall.

“With more and more testing done at states, these numbers would not be representative of the testing being done nationally,” Nancy Messonnier, the chief CDC official for respiratory diseases, said at the time. “States are reporting results quickly, and in the event of a discrepancy between CDC and state case counts, the state case counts should always be considered more up to date.”

Then, last night, the CDC resumed reporting the number of tests that the agency itself has completed, but did not include testing by state public-health departments or other laboratories. Asked to respond to our own tally and reporting, the CDC directed us to Messonnier’s statement from Tuesday.

Our reporting found that disorder has followed the CDC’s decision not to publish state data. Messonnier’s statement itself implies that, as highly populous states like California increase their own testing, the number of people the CDC reports as having been tested and the actual number of people tested will become ever more divergent. The federal tally of positive cases is now also badly out of date: While the CDC is reporting 99 positive cases of the coronavirus in the United States, our data, and separate data from Johns Hopkins University, show that the true number is well above 200, including those on the Diamond Princess cruise ship.

The White House declined to comment.

The haphazard debut of the tests—and the ensuing absence of widespread data about the epidemic—has hamstrung doctors, politicians, and public-health officials as they try to act prudently during the most important week for the epidemic in the United States so far.

Our reporting found that the capacity to test for the coronavirus varies dramatically—and sometimes dangerously—from state to state.

California claims the highest testing capacity of any state, and has tested the most individuals so far. As of yesterday afternoon, it had tested 516 people, with 53 positive cases, a spokesperson for the Department of Health told us. The department now has the capacity to test 6,000 people every day, and it expects that capacity to expand to 7,400 people a day starting today, the spokesperson said.

Washington State, the site of the country’s largest outbreak thus far, can test roughly 1,000 people a day. The state health department’s laboratory can test 100 people a day; the rest of the testing is being done at the University of Washington’s Virology Lab. Officials have found 70 positive cases in Washington so far, though a genetic study has estimated that there may be hundreds of untested people who have COVID-19 in the greater Seattle area.

Oregon, situated between the California and Washington hot spots, can test only about 40 people a day. Texas has 16 positive cases, according to media reports, but the health department’s website still lists only three casesThe Texas Tribunehas reported that the state can test approximately 30 people a day.

Other states can test even fewer. Hawaii can test fewer than 20 people a day, though it could double that number in an emergency, an official told us. Iowa has supplies to test about 500 patients a day. Arkansas, though not near a current known outbreak, is able to test only four or five patients a day.

On the East Coast, testing capacity varies significantly. New York State has 22 positive cases, including several cases of community transmission in Manhattan and Brooklyn. It can test 100 to 200 people a day. Neighboring New Jersey and Connecticut have not shared any information about how many tests they have run, or about their daily testing capacity.

Pennsylvania can test only about a dozen people a day, and Delaware can test about 50 people, our survey found. An official in Massachusetts, where two of 20 tests have come back positive, said that she did not know the Bay State’s daily capacity, but that its health department “currently [has] an adequate supply of test kits.”

These data come with an important caveat. Currently, most labs require two specimens to test one person. Single-specimen testing capability is being developed, but right now the top-line number of available tests should be cut in half. In other words, “1.5 million tests” should be able to test roughly 750,000 people. Some states, such as Colorado, told us how many specimens they could test a day (160), not how many patients (about 80). Other states shared the number of patients they could test, but not the number of specimens. In this story, we’ve standardized these numbers by dividing any specimen figure by two to give an estimate of the number of patients who can be tested.

Our reporting found that three factors determine the number of people who are tested for the coronavirus.

The first factor is the availability of tests. Until recently, very few physical tests were available, because of a mistake that the CDC made with a crucial component. The White House has pushed for and highlighted a massive increase in available tests, to perhaps 1 million in the next week. But labs have to be trained on how to set up and execute the relatively complex procedure.

The second factor is that the CDC sets the parameters for state and local public-health staff regarding who should be tested. The agency’s guidelines were very strict for weeks, focusing on returning international travelers. Even as they have been loosened in the past few days, there are persistent reports that people—including a sick nurse who had cared for a coronavirus patient—have not been able to get tested.

Finally, the more people who contract the illness, the greater the demand for testing. Some weeks ago, the number of cases in the United States was probably much, much smaller than today. The upshot is that there is likely to be an explosion of Americans tested for the coronavirus in the next week, led by California and Washington, each of which has a substantial number of cases and has shown signs that the virus is spreading.

Even in an emergency, laboratories cannot be spun up immediately. The University of Washington, which appears to have the country’s largest testing capacity outside of California—it can test up to 1,000 people a day—has been working on its own coronavirus test for several weeks.

A week ago, the FDA eased some regulations on the types of coronavirus tests that can be used. This means that testing capacity will increase, but not overnight.

It has not always been so challenging to get estimates of the number of Americans tested. Throughout February, the CDC published a regular tally of Americans who had been tested for the pathogen. Last Saturday, several days after the country’s first case of community transmission was confirmed, that figure was 472.

Then the agency stopped updating the tally. It did not publish new numbers of how many Americans had been tested for the virus on Sunday or Monday, as public criticism of the sluggish response to the disease began to mount. On Tuesday, it announced that it would stop publishing the figure altogether.

Our reporting has found that the CDC has not made good on Messonnier’s assurance that state numbers would be available and up to date. Many states are not reporting their results quickly: In our survey, we found that in some states, the most recently available numbers were days old.

Since the CDC’s pullback, it has become extremely difficult to track the nation’s growing capacity to test for the coronavirus.

There are material reasons for this. At first, the CDC did all the testing, so its results were easy to report. But as the outbreak grew, state public-health laboratories were brought into action. Each of them can do only so many tests, however, so university research laboratories have now joined the effort. Soon private laboratories such as LabCorp and Quest Diagnostics will begin testing people too. Both companies announced yesterday that doctors can now order tests. Still, no one is quite sure precisely when this new testing capability will start delivering results at scale.*

The more entities involved, the more complex the data-gathering effort grows. State public-health departments should be tracking tests from university labs and eventually private labs, but in this time of crisis, they may not have the capacity to gather those data. For example, a Washington public-health official told us that the state could test up to 100 people, but as noted, the University of Washington has far higher throughput. That suggests a positive implication of our reporting: more capacity nationwide than our, or any, data reflect.

As more laboratories join in the effort, quality control will become more difficult. While each lab must have the FDA’s permission to operate, under an Emergency Use Authorization, a new FDA policy allows labs to immediately begin testing people, and requires that they submit their paperwork to the agency within the next 15 days.

These types of measures are necessary because the United States’ response to the coronavirus is far behind the spread of the disease within its borders. Testing is the first and most important tool in understanding the epidemiology of a disease outbreak. In the United States, a series of failures has combined with the decentralized nature of our health-care system to handicap the nation’s ability to see the severity of the outbreak in hard numbers.

Today, more than a week after the country’s first case of community transmission, the most significant finding about the coronavirus’s spread in the United States has come from an independent genetic study, not from field data collected by the government. And no state or city has banned large gatherings or implemented the type of aggressive “social distancing” policies employed to battle the virus in Italy, Hong Kong, and other affluent places.

If the true extent of the outbreak were known through testing, the American situation would look worse. But health-care officials and providers would be better positioned to combat the virus. Hard decisions require data. For now, state and local governments don’t have the information they need.

This story has been updated with new information about testing capabilities at LabCorp and Quest Diagnostics.

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.